Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel (Albumin-bound), Apatinib, and Adebrelimab in Gastric/GEJ Cancer
NCT06415669Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab, Rivoceranib, paclitaxel in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by First Affiliated Hospital of Xiamen University. Started May 2024; status: recruiting.
02
Drugs
adebrelimabRivoceranibpaclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06415669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06415669.